Stratec Biomedical AG (ETR:SBS) received a €56.00 ($65.88) price target from research analysts at Deutsche Bank AG in a research report issued to clients and investors on Tuesday. The firm currently has a “neutral” rating on the stock.

A number of other equities research analysts have also recently issued reports on SBS. Oddo Securities set a €58.00 ($68.24) price objective on shares of Stratec Biomedical AG and gave the stock a “neutral” rating in a report on Monday, July 24th. Berenberg Bank set a €59.00 ($69.41) price objective on shares of Stratec Biomedical AG and gave the stock a “neutral” rating in a report on Tuesday, July 25th. Warburg Research set a €62.00 ($72.94) price objective on shares of Stratec Biomedical AG and gave the stock a “buy” rating in a report on Tuesday, July 25th. Kepler Capital Markets set a €66.00 ($77.65) price objective on shares of Stratec Biomedical AG and gave the stock a “buy” rating in a report on Wednesday, July 26th. Finally, Oddo Bhf set a €58.00 ($68.24) price objective on shares of Stratec Biomedical AG and gave the stock a “neutral” rating in a report on Monday. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of €59.50 ($70.00).

Shares of Stratec Biomedical AG (ETR:SBS) traded down 0.05% on Tuesday, hitting €56.68. The company’s stock had a trading volume of 10 shares. The stock’s 50 day moving average price is €53.30 and its 200 day moving average price is €55.24. Stratec Biomedical AG has a 52 week low of €41.45 and a 52 week high of €63.18. The stock has a market capitalization of €673.81 million and a P/E ratio of 35.01.

COPYRIGHT VIOLATION NOTICE: “Deutsche Bank AG Analysts Give Stratec Biomedical AG (SBS) a €56.00 Price Target” was first reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/10/24/deutsche-bank-ag-analysts-give-stratec-biomedical-ag-sbs-a-56-00-price-target.html.

Stratec Biomedical AG Company Profile

STRATEC Biomedical AG designs and manufactures solutions for automated processes in the fields of in vitro diagnostics and life sciences. The company operates through two segments, Instrumentation and All Other segments. It offers instrumentation products, such as automated analyzer systems, including THOLOS VMI-100, GEMINI, and GEMINI Combo for use in clinical diagnostics and biotechnology to laboratories, blood banks, and research institutes.

Analyst Recommendations for Stratec Biomedical AG (ETR:SBS)

Receive News & Ratings for Stratec Biomedical AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stratec Biomedical AG and related companies with MarketBeat.com's FREE daily email newsletter.